Orexo starts patient dosing in Phase III study of opioid dependence drug

by on June 22, 2013

Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology)

MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Previous post:

Next post: